COX-2–selective inhibitors are effective pharmacologic agents, but their use in cancer patients who are predisposed to thrombotic complications is problematic, as these drugs are associated with an enhanced risk of adverse cardiovascular events (22–24). This evidence concerns the gene PTGER2 and cancer.